249 related articles for article (PubMed ID: 23572510)
1. Regulated recycling of mutant CFTR is partially restored by pharmacological treatment.
Holleran JP; Zeng J; Frizzell RA; Watkins SC
J Cell Sci; 2013 Jun; 126(Pt 12):2692-703. PubMed ID: 23572510
[TBL] [Abstract][Full Text] [Related]
2. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
[TBL] [Abstract][Full Text] [Related]
3. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
4. Correctors of mutant CFTR enhance subcortical cAMP-PKA signaling through modulating ezrin phosphorylation and cytoskeleton organization.
Abbattiscianni AC; Favia M; Mancini MT; Cardone RA; Guerra L; Monterisi S; Castellani S; Laselva O; Di Sole F; Conese M; Zaccolo M; Casavola V
J Cell Sci; 2016 Mar; 129(6):1128-40. PubMed ID: 26823603
[TBL] [Abstract][Full Text] [Related]
5. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform.
Holleran JP; Glover ML; Peters KW; Bertrand CA; Watkins SC; Jarvik JW; Frizzell RA
Mol Med; 2012 May; 18(1):685-96. PubMed ID: 22396015
[TBL] [Abstract][Full Text] [Related]
7. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.
Pasyk S; Molinski S; Ahmadi S; Ramjeesingh M; Huan LJ; Chin S; Du K; Yeger H; Taylor P; Moran MF; Bear CE
Proteomics; 2015 Jan; 15(2-3):447-61. PubMed ID: 25330774
[TBL] [Abstract][Full Text] [Related]
8. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
Yu W; Kim Chiaw P; Bear CE
J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
[TBL] [Abstract][Full Text] [Related]
9. Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator.
Gentzsch M; Chang XB; Cui L; Wu Y; Ozols VV; Choudhury A; Pagano RE; Riordan JR
Mol Biol Cell; 2004 Jun; 15(6):2684-96. PubMed ID: 15075371
[TBL] [Abstract][Full Text] [Related]
10. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
[TBL] [Abstract][Full Text] [Related]
11. Rescue of functional F508del cystic fibrosis transmembrane conductance regulator by vasoactive intestinal peptide in the human nasal epithelial cell line JME/CF15.
Rafferty S; Alcolado N; Norez C; Chappe F; Pelzer S; Becq F; Chappe V
J Pharmacol Exp Ther; 2009 Oct; 331(1):2-13. PubMed ID: 19584307
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
[TBL] [Abstract][Full Text] [Related]
13. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.
Farinha CM; Matos P; Amaral MD
FEBS J; 2013 Sep; 280(18):4396-406. PubMed ID: 23773658
[TBL] [Abstract][Full Text] [Related]
14. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
[TBL] [Abstract][Full Text] [Related]
15. Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222.
Singh AK; Fan Y; Balut C; Alani S; Manelli AM; Swensen AM; Jia Y; Neelands TR; Vortherms TA; Liu B; Searle XB; Wang X; Gao W; Hwang TC; Ren HY; Cyr D; Kym PR; Conrath K; Tse C
J Pharmacol Exp Ther; 2020 Jan; 372(1):107-118. PubMed ID: 31732698
[TBL] [Abstract][Full Text] [Related]
16. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
[TBL] [Abstract][Full Text] [Related]
17. A chemical corrector modifies the channel function of F508del-CFTR.
Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
[TBL] [Abstract][Full Text] [Related]
18. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect.
Robert R; Carlile GW; Pavel C; Liu N; Anjos SM; Liao J; Luo Y; Zhang D; Thomas DY; Hanrahan JW
Mol Pharmacol; 2008 Feb; 73(2):478-89. PubMed ID: 17975008
[TBL] [Abstract][Full Text] [Related]
19. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
[TBL] [Abstract][Full Text] [Related]
20. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
Sampson HM; Lam H; Chen PC; Zhang D; Mottillo C; Mirza M; Qasim K; Shrier A; Shyng SL; Hanrahan JW; Thomas DY
Orphanet J Rare Dis; 2013 Jan; 8():11. PubMed ID: 23316740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
